 | • レポートコード：MRC308GR11339 • 出版社/出版日：GlobalInfoResearch / 2023年8月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
GlobalInfoResearchの最新の調査によると、世界の活性結核治療の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の活性結核治療市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。
市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。
本レポートの主な目的は次のとおりです。
– 世界および主要国の市場機会の規模を決定するため
– 活性結核治療の成長可能性を評価するため
– 各製品および最終用途市場の将来の成長を予測するため
– 市場に影響を与える競争要因を評価するため
活性結核治療市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。
種類別セグメント
・リファンピン、ピラジナミド、エタンブトール
用途別セグメント
・病院薬局、ドラッグストア＆小売薬局、オンライン薬局
主要な市場プレーヤー
・Lupin、Sanofi、Pfizer Inc.、FRESENIUS SE & Co、KGaA (Fresenius Kabi)、Johnson & Johnson、Novartis AG、Macleods Pharmaceuticals Ltd.、ANI Pharmaceuticals, Inc.、Otsuka Pharmaceutical Co., Ltd.、Teva Pharmaceutical Industries Ltd.
地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）
本調査レポートの内容は計15章あります。
・第1章では、活性結核治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な活性結核治療メーカーの企業概要、2019年～2022年までの活性結核治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な活性結核治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別活性結核治療の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの活性結核治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での活性結核治療市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および活性結核治療の産業チェーンを掲載しています。
・第14、15章では、活性結核治療の販売チャネル、販売業者、顧客、調査結果について説明します。
***** 目次(一部) *****
・市場概要
– 活性結核治療の概要
– 種類別分析（2018年vs2022年vs2029年）：リファンピン、ピラジナミド、エタンブトール
– 用途別分析（2018年vs2022年vs2029年）：病院薬局、ドラッグストア＆小売薬局、オンライン薬局
– 世界の活性結核治療市場規模・予測
– 世界の活性結核治療生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Lupin、Sanofi、Pfizer Inc.、FRESENIUS SE & Co、KGaA (Fresenius Kabi)、Johnson & Johnson、Novartis AG、Macleods Pharmaceuticals Ltd.、ANI Pharmaceuticals, Inc.、Otsuka Pharmaceutical Co., Ltd.、Teva Pharmaceutical Industries Ltd.
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：リファンピン、ピラジナミド、エタンブトール
・用途別分析2018年-2029年：病院薬局、ドラッグストア＆小売薬局、オンライン薬局
・活性結核治療の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・活性結核治療のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・活性結核治療のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・活性結核治療の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・活性結核治療の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
1 Market Overview
1.1 Product Overview and Scope of Active Tuberculosis Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Active Tuberculosis Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Rifampin
1.3.3 Pyrazinamide
1.3.4 Ethambutol
1.4 Market Analysis by Application
1.4.1 Overview: Global Active Tuberculosis Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacies
1.4.3 Drug Stores and Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Global Active Tuberculosis Treatment Market Size & Forecast
1.5.1 Global Active Tuberculosis Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Active Tuberculosis Treatment Sales Quantity (2018-2029)
1.5.3 Global Active Tuberculosis Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Lupin
2.1.1 Lupin Details
2.1.2 Lupin Major Business
2.1.3 Lupin Active Tuberculosis Treatment Product and Services
2.1.4 Lupin Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Lupin Recent Developments/Updates
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Active Tuberculosis Treatment Product and Services
2.2.4 Sanofi Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Sanofi Recent Developments/Updates
2.3 Pfizer Inc.
2.3.1 Pfizer Inc. Details
2.3.2 Pfizer Inc. Major Business
2.3.3 Pfizer Inc. Active Tuberculosis Treatment Product and Services
2.3.4 Pfizer Inc. Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Inc. Recent Developments/Updates
2.4 FRESENIUS SE & Co
2.4.1 FRESENIUS SE & Co Details
2.4.2 FRESENIUS SE & Co Major Business
2.4.3 FRESENIUS SE & Co Active Tuberculosis Treatment Product and Services
2.4.4 FRESENIUS SE & Co Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 FRESENIUS SE & Co Recent Developments/Updates
2.5 KGaA (Fresenius Kabi)
2.5.1 KGaA (Fresenius Kabi) Details
2.5.2 KGaA (Fresenius Kabi) Major Business
2.5.3 KGaA (Fresenius Kabi) Active Tuberculosis Treatment Product and Services
2.5.4 KGaA (Fresenius Kabi) Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 KGaA (Fresenius Kabi) Recent Developments/Updates
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson Active Tuberculosis Treatment Product and Services
2.6.4 Johnson & Johnson Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Johnson & Johnson Recent Developments/Updates
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Active Tuberculosis Treatment Product and Services
2.7.4 Novartis AG Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis AG Recent Developments/Updates
2.8 Macleods Pharmaceuticals Ltd.
2.8.1 Macleods Pharmaceuticals Ltd. Details
2.8.2 Macleods Pharmaceuticals Ltd. Major Business
2.8.3 Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Product and Services
2.8.4 Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Macleods Pharmaceuticals Ltd. Recent Developments/Updates
2.9 ANI Pharmaceuticals, Inc.
2.9.1 ANI Pharmaceuticals, Inc. Details
2.9.2 ANI Pharmaceuticals, Inc. Major Business
2.9.3 ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Product and Services
2.9.4 ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 ANI Pharmaceuticals, Inc. Recent Developments/Updates
2.10 Otsuka Pharmaceutical Co., Ltd.
2.10.1 Otsuka Pharmaceutical Co., Ltd. Details
2.10.2 Otsuka Pharmaceutical Co., Ltd. Major Business
2.10.3 Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Product and Services
2.10.4 Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments/Updates
2.11 Teva Pharmaceutical Industries Ltd.
2.11.1 Teva Pharmaceutical Industries Ltd. Details
2.11.2 Teva Pharmaceutical Industries Ltd. Major Business
2.11.3 Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Product and Services
2.11.4 Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
3 Competitive Environment: Active Tuberculosis Treatment by Manufacturer
3.1 Global Active Tuberculosis Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Active Tuberculosis Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Active Tuberculosis Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Active Tuberculosis Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Active Tuberculosis Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Active Tuberculosis Treatment Manufacturer Market Share in 2022
3.5 Active Tuberculosis Treatment Market: Overall Company Footprint Analysis
3.5.1 Active Tuberculosis Treatment Market: Region Footprint
3.5.2 Active Tuberculosis Treatment Market: Company Product Type Footprint
3.5.3 Active Tuberculosis Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Active Tuberculosis Treatment Market Size by Region
4.1.1 Global Active Tuberculosis Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Active Tuberculosis Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Active Tuberculosis Treatment Average Price by Region (2018-2029)
4.2 North America Active Tuberculosis Treatment Consumption Value (2018-2029)
4.3 Europe Active Tuberculosis Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Active Tuberculosis Treatment Consumption Value (2018-2029)
4.5 South America Active Tuberculosis Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Active Tuberculosis Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Active Tuberculosis Treatment Sales Quantity by Type (2018-2029)
5.2 Global Active Tuberculosis Treatment Consumption Value by Type (2018-2029)
5.3 Global Active Tuberculosis Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Active Tuberculosis Treatment Sales Quantity by Application (2018-2029)
6.2 Global Active Tuberculosis Treatment Consumption Value by Application (2018-2029)
6.3 Global Active Tuberculosis Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Active Tuberculosis Treatment Sales Quantity by Type (2018-2029)
7.2 North America Active Tuberculosis Treatment Sales Quantity by Application (2018-2029)
7.3 North America Active Tuberculosis Treatment Market Size by Country
7.3.1 North America Active Tuberculosis Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Active Tuberculosis Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Active Tuberculosis Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Active Tuberculosis Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Active Tuberculosis Treatment Market Size by Country
8.3.1 Europe Active Tuberculosis Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Active Tuberculosis Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Active Tuberculosis Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Active Tuberculosis Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Active Tuberculosis Treatment Market Size by Region
9.3.1 Asia-Pacific Active Tuberculosis Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Active Tuberculosis Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Active Tuberculosis Treatment Sales Quantity by Type (2018-2029)
10.2 South America Active Tuberculosis Treatment Sales Quantity by Application (2018-2029)
10.3 South America Active Tuberculosis Treatment Market Size by Country
10.3.1 South America Active Tuberculosis Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Active Tuberculosis Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Active Tuberculosis Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Active Tuberculosis Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Active Tuberculosis Treatment Market Size by Country
11.3.1 Middle East & Africa Active Tuberculosis Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Active Tuberculosis Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Active Tuberculosis Treatment Market Drivers
12.2 Active Tuberculosis Treatment Market Restraints
12.3 Active Tuberculosis Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Active Tuberculosis Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Active Tuberculosis Treatment
13.3 Active Tuberculosis Treatment Production Process
13.4 Active Tuberculosis Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Active Tuberculosis Treatment Typical Distributors
14.3 Active Tuberculosis Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table 1. Global Active Tuberculosis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Active Tuberculosis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Lupin Basic Information, Manufacturing Base and Competitors
Table 4. Lupin Major Business
Table 5. Lupin Active Tuberculosis Treatment Product and Services
Table 6. Lupin Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Lupin Recent Developments/Updates
Table 8. Sanofi Basic Information, Manufacturing Base and Competitors
Table 9. Sanofi Major Business
Table 10. Sanofi Active Tuberculosis Treatment Product and Services
Table 11. Sanofi Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Sanofi Recent Developments/Updates
Table 13. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Inc. Major Business
Table 15. Pfizer Inc. Active Tuberculosis Treatment Product and Services
Table 16. Pfizer Inc. Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer Inc. Recent Developments/Updates
Table 18. FRESENIUS SE & Co Basic Information, Manufacturing Base and Competitors
Table 19. FRESENIUS SE & Co Major Business
Table 20. FRESENIUS SE & Co Active Tuberculosis Treatment Product and Services
Table 21. FRESENIUS SE & Co Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. FRESENIUS SE & Co Recent Developments/Updates
Table 23. KGaA (Fresenius Kabi) Basic Information, Manufacturing Base and Competitors
Table 24. KGaA (Fresenius Kabi) Major Business
Table 25. KGaA (Fresenius Kabi) Active Tuberculosis Treatment Product and Services
Table 26. KGaA (Fresenius Kabi) Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. KGaA (Fresenius Kabi) Recent Developments/Updates
Table 28. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 29. Johnson & Johnson Major Business
Table 30. Johnson & Johnson Active Tuberculosis Treatment Product and Services
Table 31. Johnson & Johnson Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Johnson & Johnson Recent Developments/Updates
Table 33. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 34. Novartis AG Major Business
Table 35. Novartis AG Active Tuberculosis Treatment Product and Services
Table 36. Novartis AG Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Novartis AG Recent Developments/Updates
Table 38. Macleods Pharmaceuticals Ltd. Basic Information, Manufacturing Base and Competitors
Table 39. Macleods Pharmaceuticals Ltd. Major Business
Table 40. Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Product and Services
Table 41. Macleods Pharmaceuticals Ltd. Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Macleods Pharmaceuticals Ltd. Recent Developments/Updates
Table 43. ANI Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 44. ANI Pharmaceuticals, Inc. Major Business
Table 45. ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Product and Services
Table 46. ANI Pharmaceuticals, Inc. Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. ANI Pharmaceuticals, Inc. Recent Developments/Updates
Table 48. Otsuka Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 49. Otsuka Pharmaceutical Co., Ltd. Major Business
Table 50. Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Product and Services
Table 51. Otsuka Pharmaceutical Co., Ltd. Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Otsuka Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 53. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 54. Teva Pharmaceutical Industries Ltd. Major Business
Table 55. Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Product and Services
Table 56. Teva Pharmaceutical Industries Ltd. Active Tuberculosis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 58. Global Active Tuberculosis Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 59. Global Active Tuberculosis Treatment Revenue by Manufacturer (2018-2023) & (USD Million)
Table 60. Global Active Tuberculosis Treatment Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 61. Market Position of Manufacturers in Active Tuberculosis Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 62. Head Office and Active Tuberculosis Treatment Production Site of Key Manufacturer
Table 63. Active Tuberculosis Treatment Market: Company Product Type Footprint
Table 64. Active Tuberculosis Treatment Market: Company Product Application Footprint
Table 65. Active Tuberculosis Treatment New Market Entrants and Barriers to Market Entry
Table 66. Active Tuberculosis Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 67. Global Active Tuberculosis Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 68. Global Active Tuberculosis Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 69. Global Active Tuberculosis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 70. Global Active Tuberculosis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 71. Global Active Tuberculosis Treatment Average Price by Region (2018-2023) & (US$/Unit)
Table 72. Global Active Tuberculosis Treatment Average Price by Region (2024-2029) & (US$/Unit)
Table 73. Global Active Tuberculosis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 74. Global Active Tuberculosis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 75. Global Active Tuberculosis Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Global Active Tuberculosis Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Global Active Tuberculosis Treatment Average Price by Type (2018-2023) & (US$/Unit)
Table 78. Global Active Tuberculosis Treatment Average Price by Type (2024-2029) & (US$/Unit)
Table 79. Global Active Tuberculosis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 80. Global Active Tuberculosis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 81. Global Active Tuberculosis Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 82. Global Active Tuberculosis Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 83. Global Active Tuberculosis Treatment Average Price by Application (2018-2023) & (US$/Unit)
Table 84. Global Active Tuberculosis Treatment Average Price by Application (2024-2029) & (US$/Unit)
Table 85. North America Active Tuberculosis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 86. North America Active Tuberculosis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 87. North America Active Tuberculosis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 88. North America Active Tuberculosis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 89. North America Active Tuberculosis Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 90. North America Active Tuberculosis Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 91. North America Active Tuberculosis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 92. North America Active Tuberculosis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Europe Active Tuberculosis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 94. Europe Active Tuberculosis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 95. Europe Active Tuberculosis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 96. Europe Active Tuberculosis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 97. Europe Active Tuberculosis Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 98. Europe Active Tuberculosis Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 99. Europe Active Tuberculosis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 100. Europe Active Tuberculosis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 101. Asia-Pacific Active Tuberculosis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 102. Asia-Pacific Active Tuberculosis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 103. Asia-Pacific Active Tuberculosis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 104. Asia-Pacific Active Tuberculosis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 105. Asia-Pacific Active Tuberculosis Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 106. Asia-Pacific Active Tuberculosis Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 107. Asia-Pacific Active Tuberculosis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 108. Asia-Pacific Active Tuberculosis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 109. South America Active Tuberculosis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 110. South America Active Tuberculosis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 111. South America Active Tuberculosis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 112. South America Active Tuberculosis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 113. South America Active Tuberculosis Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 114. South America Active Tuberculosis Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 115. South America Active Tuberculosis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 116. South America Active Tuberculosis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 117. Middle East & Africa Active Tuberculosis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 118. Middle East & Africa Active Tuberculosis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 119. Middle East & Africa Active Tuberculosis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 120. Middle East & Africa Active Tuberculosis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 121. Middle East & Africa Active Tuberculosis Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 122. Middle East & Africa Active Tuberculosis Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 123. Middle East & Africa Active Tuberculosis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 124. Middle East & Africa Active Tuberculosis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 125. Active Tuberculosis Treatment Raw Material
Table 126. Key Manufacturers of Active Tuberculosis Treatment Raw Materials
Table 127. Active Tuberculosis Treatment Typical Distributors
Table 128. Active Tuberculosis Treatment Typical Customers
List of Figures
Figure 1. Active Tuberculosis Treatment Picture
Figure 2. Global Active Tuberculosis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Active Tuberculosis Treatment Consumption Value Market Share by Type in 2022
Figure 4. Rifampin Examples
Figure 5. Pyrazinamide Examples
Figure 6. Ethambutol Examples
Figure 7. Global Active Tuberculosis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Active Tuberculosis Treatment Consumption Value Market Share by Application in 2022
Figure 9. Hospital Pharmacies Examples
Figure 10. Drug Stores and Retail Pharmacies Examples
Figure 11. Online Pharmacies Examples
Figure 12. Global Active Tuberculosis Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Active Tuberculosis Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Active Tuberculosis Treatment Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Active Tuberculosis Treatment Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Active Tuberculosis Treatment Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Active Tuberculosis Treatment Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Active Tuberculosis Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Active Tuberculosis Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Active Tuberculosis Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Active Tuberculosis Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Active Tuberculosis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Active Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Active Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Active Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Active Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Active Tuberculosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Active Tuberculosis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Active Tuberculosis Treatment Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Active Tuberculosis Treatment Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Active Tuberculosis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Active Tuberculosis Treatment Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Active Tuberculosis Treatment Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Active Tuberculosis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Active Tuberculosis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Active Tuberculosis Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Active Tuberculosis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Active Tuberculosis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Active Tuberculosis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Active Tuberculosis Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Active Tuberculosis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Active Tuberculosis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Active Tuberculosis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Active Tuberculosis Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Active Tuberculosis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 54. China Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Active Tuberculosis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Active Tuberculosis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Active Tuberculosis Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Active Tuberculosis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Active Tuberculosis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Active Tuberculosis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Active Tuberculosis Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Active Tuberculosis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Active Tuberculosis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Active Tuberculosis Treatment Market Drivers
Figure 75. Active Tuberculosis Treatment Market Restraints
Figure 76. Active Tuberculosis Treatment Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Active Tuberculosis Treatment in 2022
Figure 79. Manufacturing Process Analysis of Active Tuberculosis Treatment
Figure 80. Active Tuberculosis Treatment Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
| 【活性結核治療について】 ※活性結核治療は、結核（TB）という感染症に対する治療を指します。結核は主に結核菌（Mycobacterium tuberculosis）によって引き起こされる感染症で、主に肺に影響を及ぼすことが多いですが、他の臓器にも感染する可能性があります。治療は一般的に長期にわたり、特定の薬剤を使用することが求められます。ここでは、活性結核治療の概念について詳しく解説していきます。 結核は、空気中の微小な飛沫を通じて人から人へと感染します。症状としては、持続的な咳、発熱、体重減少、夜間の発汗などが見られます。結核が疑われる場合、まずは医療機関での診断が必要であり、診断には胸部X線撮影や痰の検査が用いられます。これにより、結核の有無や感染の広がりが確認されます。 活性結核の治療は、抗結核薬を使用することによって行われます。治療の基本は、通常、2ヶ月間の集中的な治療と、その後の4ヶ月間の維持治療の8ヶ月間のコースで構成されることが一般的です。この間に使用される主な薬剤には、イソニアジド、リファンピシン、ピラジナミド、エタンブトールなどがあります。これらの薬剤はそれぞれ異なる方式で結核菌を抑制します。 一つの大きな特徴は、結核治療は長期にわたるため、患者の治療アドヒアランス（治療の遵守）が非常に重要であるという点です。効果的な治療を行うためには、患者が処方された薬を規則正しく服用し続ける必要があります。治療を途中で中断すると、結核菌が耐性を持つようになり、従来の抗結核薬が効かなくなる多剤耐性結核（MDR-TB）や、深刻な場合には広範囲耐性結核（XDR-TB）が発生するリスクがあります。 結核治療においては、個々の患者に応じた治療計画が必要です。例えば、既に他の病気（他の感染症や慢性疾患等）を抱えている患者の場合、治療方針が異なることがあります。また、新たに発見された治療薬や新技術の導入も、治療の選択肢を広げる要因となります。 治療過程においては、定期的なフォローアップが重要であり、患者の状態を見守るために定期的な診察や検査が行われます。これにより治療の効果が確認され、副作用の管理も行われます。結核治療は多くの場合、患者の生活の質を大きく改善するだけでなく、感染拡大を防ぐためにも重要です。治療が完了しても、再発の可能性や感染リスクへの配慮が求められます。 関連した技術としては、結核予防ワクチン（BCGワクチン）が存在します。このワクチンは特に小児に対して接種され、重症結核や髄膜炎からの予防効果が期待されています。予防医学の観点から、スクリーニング検査や、感染が確認された場合の早期治療が重要視されています。また、近年では結核の早期診断を目的とした新技術も開発されており、分子検査（PCR検査）などが急速に進展しています。これにより、より迅速かつ正確な診断が可能となり、早期治療につながることが期待されています。 さらに、テレメディスンやデジタルヘルス技術も活用されるようになり、遠隔地にいる患者の状態をモニタリングしたり、治療計画を柔軟に変更したりすることができるようになっています。これにより、患者の生活環境や個々のニーズに応じた適切な支援が行えるようになります。 活性結核治療は、単に患者の症状の改善を目指すだけでなく、公共衛生の観点からも重要な意味を持っています。世界的には結核は依然として深刻な健康問題であり、特に発展途上国では感染が広がるリスクが高いです。そのため、国際的な協力や対策が求められています。基盤となるのは、結核に対する認識を高め、早期診断と適切な治療を普及させることです。COVID-19のパンデミックにおいても、結核治療が後回しにされるケースが増加し、これによって結核患者が適切な治療を受けられないリスクが高まっている事態も問題視されています。 このように、活性結核治療は医学的な側面と公共衛生、安全保障など多方面にわたって影響を及ぼす重要なテーマです。今後の進展には、治療法の改善とともに、結核に対する意識向上ならびに社会全体での取り組みが必要不可欠です。特に医療従事者の教育やコミュニティにおける啓発活動は、結核の撲滅に向けた鍵となるでしょう。この感染症に対する取り組みが社会全体で強化されることで、結核による公衆衛生への影響を低減し、より健康的な社会を実現することが期待されます。 |
